Cocrystal Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COCRYSTAL PHARMA, INC. | ||
| March 28, 2024 | By: | /s/ James Martin |
|---|---|---|
| James Martin Co-Interim Chief Executive Officer (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Roger Kornberg | Chairman | March 28, 2024 |
| Roger Kornberg | ||
| /s/ Phillip Frost | Director | March 28, 2024 |
| Phillip Frost | ||
| /s/ Fred Hassan | Director | March 28, 2024 |
| Fred Hassan | ||
| /s/ Steven Rubin | Director | March 28, 2024 |
| Steven Rubin | ||
| /s/ Richard Pfenniger | Director | March 28, 2024 |
| Richard Pfenniger | ||
| /s/ Anthony Japour | Director | March 28, 2024 |
| Anthony Japour | ||
| /s/ James Martin | Chief Financial Officer and Co-Chief Executive Officer (Principal Financial, Accounting and Executive Officer) | March 28, 2024 |
| James Martin | ||
| /s/ Sam Lee | President and Co-Chief Executive Officer (Principal Executive Officer) | March 28, 2024 |
| Sam Lee | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.